MAPK1 and lung carcinoma: The dysregulation and activation of the MAPK1/3 signaling pathway have been strongly correlated with the initiation and progression of diverse tumors (45–47), including but not limited to lung cancer (48), breast cancer (49), and liver cancer (50).